Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model.

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
15 May 2020
Historique:
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 9 6 2020
Statut: epublish

Résumé

The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.

Identifiants

DOI: 10.1101/2020.05.11.088674 PMID: 32511387 PMC: PMC7263516
pubmed: 32511387
doi: 10.1101/2020.05.11.088674
pmc: PMC7263516
pii:
doi:

Types de publication

Preprint

Langues

eng

Commentaires et corrections

Type : UpdateIn

Références

J Virol. 2004 Sep;78(17):9007-15
pubmed: 15308697
Nat Commun. 2015 Sep 15;6:8223
pubmed: 26370782
Adv Immunol. 2001;77:195-262
pubmed: 11293117
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685
pubmed: 32152119
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
Pediatrics. 1998 Sep;102(3 Pt 1):531-7
pubmed: 9738173
J Virol. 2005 Jan;79(1):503-11
pubmed: 15596843
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593
Science. 2016 Mar 18;351(6279):1343-6
pubmed: 26917592
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Nat Rev Immunol. 2018 May;18(5):297-308
pubmed: 29379211
Cell. 2019 May 30;177(6):1566-1582.e17
pubmed: 31104840
Immunity. 2018 Feb 20;48(2):339-349.e5
pubmed: 29396163
J Virol. 2007 Mar;81(5):2418-28
pubmed: 17166901

Auteurs

Thomas F Rogers (TF)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

Fangzhu Zhao (F)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

Deli Huang (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Nathan Beutler (N)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Alison Burns (A)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

Wan-Ting He (WT)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Oliver Limbo (O)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI, New York, NY10004, USA.

Chloe Smith (C)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

Ge Song (G)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Jordan Woehl (J)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI, New York, NY10004, USA.

Linlin Yang (L)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Robert K Abbott (RK)

La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

Sean Callaghan (S)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Elijah Garcia (E)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Jonathan Hurtado (J)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Mara Parren (M)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Linghang Peng (L)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

James Ricketts (J)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Michael J Ricciardi (MJ)

George Washington University, Washington, DC 20052, USA.

Stephen A Rawlings (SA)

Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

Davey M Smith (DM)

Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

David Nemazee (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

John R Teijaro (JR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

James E Voss (JE)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Raiees Andrabi (R)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Bryan Briney (B)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Elise Landais (E)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI, New York, NY10004, USA.

Devin Sok (D)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI, New York, NY10004, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Joseph G Jardine (JG)

IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI, New York, NY10004, USA.

Dennis R Burton (DR)

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.

Classifications MeSH